STOCK TITAN

Jazz Pharmaceuticals Plc - JAZZ STOCK NEWS

Welcome to our dedicated page for Jazz Pharmaceuticals Plc news (Ticker: JAZZ), a resource for investors and traders seeking the latest updates and insights on Jazz Pharmaceuticals Plc stock.

Overview

Jazz Pharmaceuticals Plc (symbol: JAZZ) is a globally recognized biopharmaceutical company dedicated to the identification, development, and commercialization of novel therapies designed to address serious unmet medical needs. Headquartered in Dublin, Ireland, the company has successfully built a diversified portfolio that focuses on areas such as sleep disorders, epilepsy, oncology, and neuroscience. Leveraging its robust research and development capabilities, Jazz Pharmaceuticals delivers innovative treatments that improve patient outcomes and transform lives across a range of therapeutic areas.

Core Business and Product Portfolio

Jazz Pharmaceuticals operates in a highly specialized industry where clinical value and regulatory excellence are key. The company’s core business is centered around the discovery and development of life-changing medicines that often serve patients with limited or no therapeutic options. Its portfolio includes a variety of therapies used to treat complex conditions, encompassing:

  • Sleep Disorders: Advanced treatment solutions that offer improved formulations for disorders such as narcolepsy.
  • Neurological Indications and Epilepsy: Cannabidiol-based therapies designed to manage seizures associated with treatment-resistant conditions, reinforcing its expertise in neuroscience.
  • Oncology: Innovative strategies and investigational therapies targeting various forms of cancer, including hematology/oncology indications.

Business Model and Market Position

The company generates revenue through multiple channels, including the commercialization of its approved therapies, licensing agreements, and strategic acquisitions that complement its existing product portfolio. Jazz Pharmaceuticals rigorously implements a science-driven approach to clinical development, ensuring that each program undergoes comprehensive clinical trials and regulatory review. This commitment to clinical excellence and consistent product performance positions Jazz as an authoritative player within the biopharmaceutical landscape.

Research and Development Excellence

At the heart of its operations lies a robust R&D engine that fuels continuous innovation. The company invests in advanced clinical studies to confirm the efficacy and safety of its product candidates. By collaborating with leading scientific experts and maintaining a highly skilled workforce, Jazz Pharmaceuticals cultivates a unique environment where scientific progress and entrepreneurial spirit combine to produce groundbreaking therapies.

Corporate Culture and Values

The company’s success is further driven by its commitment to a collaborative and flexible culture. Core values such as integrity, innovation, passion, and the pursuit of excellence guide every decision, ensuring that Jazz Pharmaceuticals remains patient-focused and responsive to the needs of the global healthcare market. This culture underpins not only its research achievements but also its strategic expansion and operational efficiency.

Industry Recognition and Expertise

Jazz Pharmaceuticals is known for its authoritative presence in the biopharmaceutical industry. Industry-specific keywords such as "clinical innovation," "regulatory excellence," and "advanced therapeutics" are integral to its identity. The company’s effective communication of complex scientific concepts and its ability to meet rigorous regulatory standards demonstrates its deep expertise and builds trust among healthcare professionals, patients, and investors.

Summary

With a diversified portfolio that spans multiple therapeutic areas and a strong commitment to innovation and scientific rigor, Jazz Pharmaceuticals Plc remains a compelling case study in how biopharmaceutical companies can drive transformational patient care while maintaining robust business operations. Its focused approach on solving unmet medical needs and its continuous development of cutting-edge therapies underscore its influential stance in the market.

Rhea-AI Summary
Jazz Pharmaceuticals (JAZZ) is committed to being a responsible corporate citizen, focusing on community engagement, volunteering, and health equity. The company emphasizes employee volunteerism, philanthropy, and partnerships to support social impact goals. In 2022, Jazz provided charitable support to over 70 organizations globally, aligning its corporate giving with patient care causes and addressing healthcare disparities. The company also encourages global volunteer days and supports local community engagement through various initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
none
-
Rhea-AI Summary
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will present nine abstracts, including real-world outcomes of Epidiolex in treatment-resistant focal epilepsies, at the 2023 American Epilepsy Society (AES) annual meeting. The abstracts will focus on U.S. caregiver-reported seizure and non-seizure outcomes in patients with tuberous sclerosis complex (TSC) prescribed Epidiolex.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
conferences
-
Rhea-AI Summary
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will present new trial results of investigational bispecific antibody zanidatamab at the 2023 San Antonio Breast Cancer Symposium (SABCS) and the 65th Annual American Society of Hematology (ASH) Annual Meeting, along with real-world data at the International Association for the Study of Lung Cancer (IASLC) 2023 North America Conference on Lung Cancer (NACLC).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.47%
Tags
conferences
Rhea-AI Summary
Jazz Pharmaceuticals (JAZZ) Corporate Sustainability and Social Impact Report 2022: Environmental Responsibility, Climate Strategy, and Water Management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.2%
Tags
none
-
Rhea-AI Summary
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announces an exclusive global licensing agreement with Autifony Therapeutics Limited for up to $770.5 million to discover and develop drug candidates targeting ion channel targets associated with neurological disorders. Autifony will lead drug discovery and preclinical development activities, while Jazz will handle clinical development, manufacturing, and commercialization. Autifony is set to receive an upfront payment and potential milestone payments, with the total deal value including royalties on future net sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.3%
Tags
none
-
Rhea-AI Summary
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced 3Q23 total revenues of $972 million, with combined revenues from key growth drivers Xywav®, Epidiolex®, and Rylaze® increasing 24% year-over-year. The company is raising total and Oncology revenue guidance at the mid-points and plans to initiate zanidatamab rolling biologics license application (BLA) submission this year for accelerated approval in second-line (2L) biliary tract cancers (BTC).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.14%
Tags
Rhea-AI Summary
Jazz Pharmaceuticals plc and The University of Texas MD Anderson Cancer Center have entered a five-year strategic research collaboration to evaluate zanidatamab, an investigational HER2-targeted bispecific antibody, in multiple HER2-expressing cancers. The collaboration aims to investigate zanidatamab's potential as monotherapy and in combination with other treatments for patients with different tumor types and stages, including early-stage breast cancer, treatment-resistant cancers, and potentially rare, tissue-agnostic cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.66%
Tags
none
-
Rhea-AI Summary
Jazz Pharmaceuticals plc will participate in upcoming investor conferences including Jefferies London Healthcare Conference, 6th Annual Evercore ISI HealthCONx Conference, and 2023 BofA Leveraged Finance Conference. Audio webcasts of the presentations will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
conferences
-
Rhea-AI Summary
Jazz Pharmaceuticals will report its 2023 Q3 financial results on November 8, 2023. A live audio webcast will be hosted to discuss the results and provide a business update. Interested parties can access the webcast via the Investors section of the Jazz Pharmaceuticals website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
conferences earnings
Rhea-AI Summary
Jazz Pharmaceuticals presents new data on cardiovascular disease risk in patients with sleep disorders and the impact of sodium intake on cardiovascular health. The company also shares results from the TENOR study on individualized dosing regimens for narcolepsy patients transitioning to low-sodium Xywav.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.71%
Tags
none

FAQ

What is the current stock price of Jazz Pharmaceuticals Plc (JAZZ)?

The current stock price of Jazz Pharmaceuticals Plc (JAZZ) is $103.38 as of April 22, 2025.

What is the market cap of Jazz Pharmaceuticals Plc (JAZZ)?

The market cap of Jazz Pharmaceuticals Plc (JAZZ) is approximately 6.2B.

What is the primary focus of Jazz Pharmaceuticals?

Jazz Pharmaceuticals focuses on developing and commercializing innovative therapies for conditions with serious unmet medical needs, particularly in areas such as sleep disorders, epilepsy, oncology, and neuroscience.

How does Jazz Pharmaceuticals generate its revenue?

The company generates revenue through the commercialization of its approved therapies, strategic licensing agreements, and acquisitions that expand its diversified product portfolio.

What distinguishes Jazz Pharmaceuticals in the biopharmaceutical industry?

Jazz Pharmaceuticals stands out due to its science-driven research and development, commitment to clinical excellence, advanced therapeutic portfolio, and a culture grounded in integrity and innovation.

Which therapeutic areas are highlighted in Jazz Pharmaceuticals' portfolio?

The company’s portfolio includes treatments for sleep disorders, neurological indications including epilepsy, and various oncology indications, supporting a broad range of patient needs.

How does Jazz Pharmaceuticals ensure its products meet regulatory standards?

The company undertakes extensive clinical trials and leverages its advanced R&D capabilities to ensure that each product meets rigorous regulatory requirements and industry standards for safety and efficacy.

What role does research and development play at Jazz Pharmaceuticals?

R&D is central to Jazz Pharmaceuticals’ operations, fueling innovation through clinical studies, collaboration with scientific experts, and continuous investment in developing groundbreaking therapies.
Jazz Pharmaceuticals Plc

Nasdaq:JAZZ

JAZZ Rankings

JAZZ Stock Data

6.25B
58.81M
3.09%
99.91%
7.19%
Biotechnology
Pharmaceutical Preparations
Link
Ireland
DUBLIN